复星医药核药项目SRT-007启动Ⅰ期临床试验

Core Viewpoint - Fosun Pharma's subsidiary Chengdu Xingrui Jingxuan Biotechnology Co., Ltd. has initiated Phase I clinical trials for the integrated diagnostic and therapeutic nuclear medicine project SRT-007 in mainland China, targeting PSMA-positive metastatic castration-resistant prostate cancer [1] Group 1: Project Details - The SRT-007 project includes two injectable solutions: Gallium [68Ga] PSMA-0057 for diagnosis and Lutetium [177Lu] PSMA-0057 for treatment [1] - Gallium [68Ga] PSMA-0057 is a radioactive drug used for diagnostic purposes, while Lutetium [177Lu] PSMA-0057 is intended for therapeutic use [1]